AGL 38.45 Decreased By ▼ -0.03 (-0.08%)
AIRLINK 197.80 Decreased By ▼ -5.22 (-2.57%)
BOP 10.05 Decreased By ▼ -0.12 (-1.18%)
CNERGY 6.33 Decreased By ▼ -0.21 (-3.21%)
DCL 9.40 Decreased By ▼ -0.18 (-1.88%)
DFML 39.40 Decreased By ▼ -0.62 (-1.55%)
DGKC 98.34 Increased By ▲ 0.26 (0.27%)
FCCL 35.65 Increased By ▲ 0.69 (1.97%)
FFBL 87.24 Increased By ▲ 0.81 (0.94%)
FFL 13.69 Decreased By ▼ -0.21 (-1.51%)
HUBC 130.70 Decreased By ▼ -0.87 (-0.66%)
HUMNL 13.95 Decreased By ▼ -0.07 (-0.5%)
KEL 5.35 Decreased By ▼ -0.26 (-4.63%)
KOSM 7.40 Increased By ▲ 0.13 (1.79%)
MLCF 45.62 Increased By ▲ 0.03 (0.07%)
NBP 61.50 Decreased By ▼ -4.88 (-7.35%)
OGDC 216.68 Decreased By ▼ -4.08 (-1.85%)
PAEL 39.35 Increased By ▲ 0.87 (2.26%)
PIBTL 8.55 Decreased By ▼ -0.36 (-4.04%)
PPL 194.01 Decreased By ▼ -3.87 (-1.96%)
PRL 39.29 Increased By ▲ 0.26 (0.67%)
PTC 26.00 Increased By ▲ 0.53 (2.08%)
SEARL 104.69 Increased By ▲ 1.64 (1.59%)
TELE 8.71 Decreased By ▼ -0.31 (-3.44%)
TOMCL 36.25 Decreased By ▼ -0.16 (-0.44%)
TPLP 13.88 Increased By ▲ 0.13 (0.95%)
TREET 24.90 Decreased By ▼ -0.22 (-0.88%)
TRG 56.90 Decreased By ▼ -1.14 (-1.96%)
UNITY 33.25 Decreased By ▼ -0.42 (-1.25%)
WTL 1.64 Decreased By ▼ -0.07 (-4.09%)
BR100 11,810 Decreased By -80.5 (-0.68%)
BR30 36,839 Decreased By -517.3 (-1.38%)
KSE100 109,961 Decreased By -1109.5 (-1%)
KSE30 34,576 Decreased By -333.5 (-0.96%)
World

Hong Kong advisory panel approves China's Sinovac COVID-19 vaccine for emergency use

  • Hong Kong's government said in early February that it was exempting Chinese drug maker Sinovac from publishing results of its third phase clinical trials in medical journals due to the "urgency" for vaccination.
  • The city's Health Secretary Sophia Chan has the final decision on whether to approve the Sinovac vaccine.
Published February 16, 2021

HONG KONG: A Hong Kong government advisory panel on COVID-19 vaccines said on Tuesday it would recommend China's Sinovac vaccine for emergency use, a move that brings it a step closer to being formally greenlighted in the Asian financial hub.

Hong Kong's government said in early February that it was exempting Chinese drug maker Sinovac from publishing results of its third phase clinical trials in medical journals due to the "urgency" for vaccination.

The Pfizer/BioNTech vaccine - the first approved by Hong Kong's Health department - was required to have published results in a medical journal before being examined by the advisory panel.

The city's Health Secretary Sophia Chan has the final decision on whether to approve the Sinovac vaccine.

Comments

Comments are closed.